Symptomatic treatment of dyspeptic symptoms not related to organic gastrointestinal disease, such as heartburn, dyspepsia, hyperacidity.
Composition:
1 tabl Effervescent contains 150 mg Ranitidine as ranitidine hydrochloride. In addition, the preparation contains aspartame and sorbitol.
Action:
Antagonist of histamine H receptors2. It inhibits the secretion of hydrochloric acid in the stomach (both basal and postprandial), and also reduces the secretion of pepsin in the stomach. A dose of 150 mg inhibits acid secretion for about 12 hours. After oral administration, it is rapidly absorbed from the gastrointestinal tract reaching a maximum plasma concentration after 2-3 hours. During the first 24 hours, about 40% of the oral dose is excreted unchanged in the urine. Ranitidine passes through the placental barrier and into breast milk.
Contraindications:
Hypersensitivity to the active substance or to any of the excipients. porphyria
Precautions:
Before starting treatment with ranitidine in patients with peptic ulcer disease, the cancerous nature of the disease should be ruled out (especially in middle-aged or elderly patients with dyspeptic symptoms not previously present or changed), because treatment with ranitidine may mask the symptoms of stomach cancer and delay diagnosis. Use with caution in patients with impaired renal function and / or liver function. In patients with impaired renal function should reduce the daily dose of the drug (ranitidine is excreted through the kidneys). The preparation should be avoided in patients with a history of acute porphyria (there are rare clinical reports indicating that ranitidine may induce severe porphyria attacks). Patients treated with non-steroidal anti-inflammatory drugs and ranitidine should undergo regular monitoring, especially in elderly patients and patients with a history of peptic ulcer. The preparation contains sorbitol, which can cause stomach irritation and diarrhea. Due to the sodium content, use the drug carefully in patients who control sodium content in the diet. Due to the content of aspartame, the drug may be harmful for patients with phenylketonuria. Due to the sorbitol content, the preparation should not be used in patients with rare hereditary fructose intolerance.
Pregnancy and lactation:
The preparation can be used during pregnancy and breastfeeding only if definitely necessary.
Side effects:
The following may occur: transient changes in liver enzymes, hepatitis with or without jaundice, acute pancreatitis, diarrhea, transient changes in the blood picture (decrease in the number of leukocytes and platelets, agranulocytosis, pancytopenia, aplastic anemia, sometimes with partial or complete inhibition of bone marrow hypersensitivity reactions that sometimes occurred after a single dose of the drug (urticaria, angioneurotic edema, fever, bronchospasm, hypotension, anaphylactic shock), bradycardia and atrioventricular block, headache (sometimes severe) and dizziness, transient involuntary movements, agitation, confusion, depression, hallucinations (especially in severely ill and elderly patients), blurred vision, skin rash (including rare cases of erythema multiforme), alopecia, vasculitis, gynecomastia, transient impotence, joint pain and muscles. Very rare: acute interstitial nephritis.
Dosage:
Orally. Adults and children over 16 years: 1 tabl. per day. Maximum 2 tables daily. If the dyspeptic symptoms last longer than 14 days, the diagnosis should be verified.Special groups of patients. Patients with renal insufficiency (creatinine clearance less than 50 ml / min): 1 tablet per day. Patients on chronic dialysis: 1 tablet immediately after dialysis. Do not use the preparation in children under 16 years of age.Way of giving. The tablet dissolve in 1/2 glass of water.
(C)
